SAN DIEGO, Feb. 27, 2015 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, today announced that it will be presenting at CALBIO 2015 at the San Francisco Marriott Marquis on March 2nd at 3pm PST. Patrick Lucy, chief business officer of Pfenex, will participate on a panel discussing the current state of the biosimilar industry landscape entitled The Evolving World of Biosimilars.
For more information on CALBIO 2015 and The Evolving World of Biosimilars panel, please visit https://www.calbio2015.org/.
Pfenex has used, and intends to continue to use, its Investor Relations website (http://pfenex.investorroom.com), as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, visit (http://pfenex.investorroom.com).
About Pfenex Inc.
Pfenex Inc. is a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics and high-value and difficult to manufacture proteins. The company's lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab), for the potential treatment of patients with retinal diseases. Pfenex has leveraged its Pfēnex Expression Technology® platform to build a pipeline of product candidates and preclinical products under development including other biosimilars, as well as vaccines, generics and next generation biologics.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pfenex-to-present-at-calbio-2015-300042655.html
SOURCE Pfenex Inc.